CHOICELY
2.5.2024 08:01:29 CEST | Business Wire | Press release
The Eurovision Song Contest (ESC), the world’s largest live music event, has renewed their mobile app in time for this year’s event in Malmö, Sweden. The app was built using Choicely’s no code app platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501446902/en/
Eurovision Song Contest built their new mobile app with a no code platform. The app was built using Choicely’s no code app platform. The Eurovision app boasts an extensive news feed and media portal, and engagement tools full of interactive fan activations like the Scoreboard. With it, viewers can establish their own classic Eurovision ranking from 12 points on, and share the ranking on social media. (Graphic: Business Wire)
“We were looking for a specialized partner who enables us to develop our app with speed and flexibility, so we can better serve the Eurovision fans across the globe,“ says Dave Goodman, ESC Digital and Communications Manager for Contest organizers, the European Broadcasting Union.
“We definitely got all of that in Choicely, and more,” Goodman emphasizes.
With Choicely, the app can be built without coding, using a visual drag and drop interface instead – like Wix or Wordpress for mobile apps.
“Despite Choicely being a no code platform, we got a fully tailormade app that matches our needs and our brand. Making improvements is quick and easy. We can focus on engaging our fans!” adds Dave Goodman from the EBU.
The Eurovision app boasts an extensive news feed and media portal, and engagement tools full of interactive fan activations like the Scoreboard. With it, viewers can establish their own classic Eurovision ranking from 12 points on, and share the ranking on social media.
During the Semi-Finals and Grand Final, viewers around the world can also easily vote through the app.
“We are proud to co-operate with the Eurovision Song Contest!” says Kaius Meskanen, CEO of Choicely. “It’s a legendary contest with a passionate global fanbase, and it reflects in everything they do,” Meskanen says.
“Together we have created a pixel-perfect app to serve the Eurovision fans, during the shows and in between them. It’s great to see the ESC organization enjoying the benefits of no code, like lower development costs, agile updates, and a better overall experience for the fans,” Meskanen points out.
Choicely was founded in Finland and it’s used by leaders in media, sports and entertainment companies, and across a range of industries in over 50 countries.
The renewed Eurovision Song Contest app can be found in Apple App Store and Google Play Store.
The Eurovision Song Contest is the world’s largest live music event. It is organized annually by the European Broadcasting Union (EBU), the world’s foremost alliance of public service media (PSM).
The competition, in which participating public service broadcasters that are Members of the EBU, send a new song to represent their nation, has taken place every year since 1956 except in 2020.
27 broadcasters have won the competition at least once.
37 broadcasters will take part in the 2024 Eurovision Song Contest in Malmö, Sweden hosted by SVT.
The 2023 competition reached over 170 million viewers around the world on TV and online.
The EBU represents 112 media organisations in 56 countries in Europe, the Middle East, and Africa; and have an additional 31 Associates in Asia, Africa, Australia, and the Americas. The EBU strives to secure a sustainable future for public service media.
Choicely’s no code app builder offers a simple, fast and affordable way to build and maintain high quality mobile apps. Choicely is based in Finland and Switzerland and currently serves businesses in over 50 countries. Choicely’s customers include the Eurovision Song Contest, Miss Universe, ITV Studios / Love Island TV Shows, and Iceland's national broadcasting organization RÚV.
Learn more about Choicely on their website.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240501446902/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom